Iris Dorbian
San Francisco-based Bay Labs, a medical technology company, has closed $5.5 million in Series A funding. Khosla Ventures led the round with participation from other investors that included Data Collective, Greenbox Venture Partners, Minneapolis Heart Institute Ventures and Georges Harik. In conjunction with the funding, Ben Ling, a general partner at Khosla Ventures, and Armen Vidian, an operating partner at DCVC, will join Bay Labs’ board of directors.
San Francisco-based game developer nWay has raised $11 million in funding. The investors included March Capital Partners and Ridge Ventures.
Manhattan Beach, California-based Curisium, a healthcare technology and services company, has raised $3.5 million in seed financing. The backers were Flare Capital Partners, New Enterprise Associates, Shuttle Fund, Sanofi Ventures and Green Bay Ventures. In conjunction with the financing, Bill Geary of Flare Capital and Mohamad Makhzoumi of NEA have joined Curisium's board of directors while Ruchita Sinha of Sanofi Ventures has become a board observer.
Boston-based Ginkgo Bioworks, an organism company, has raised $275 million in Series D funding. The investors included Viking Global, Y Combinator's Continuity Fund, Cascade Investment and General Atlantic.
Oakland, California-based Elemeno Health, a digital health startup, has secured $1.3 million in seed funding. Launchpad Digital Health led the round.
Los Altos, California-based Cibiem Inc, a medical device company, has appointed William H. Kucheman to its board of directors. Currently, Kucheman served as director of BioStar Ventures III, a medical device venture capital fund. Cibiem is backed by Third Rock Ventures, SV Health Investors and BioStar Ventures.
Menlo Park, California-based GRAIL Inc, a life sciences company focused on detecting cancer early when it can be cured, has named Jennifer Cook as CEO. Her appointment becomes effective January 2, 2018. Bill Rastetter, the interim CEO since August 2017, will continue as chairman of the board of directors. And GRAIL has added Catherine Friedman and Min Cui to its board of directors. GRAIL's backers include ARCH Venture Partners, Amazon, Bezos Expeditions, Bill Gates, Bristol-Myers Squibb, Celgene, Decheng Capital, GV, Illumina, Johnson & Johnson Innovation, Merck, McKesson Ventures, Sutter Hill Ventures, Tencent and Varian Medical Systems.
Cambridge, Massachusetts-based Relay Therapeutics, a biotech company, has closed $63 million in Series B financing. BVF Partners led the round with participation from GV, Casdin Capital, EcoR1 Capital, Section 32, Third Rock Ventures and Alexandria Venture Investments. In conjunction with the funding, Kanishka Pothula, a managing director at BVF Partners, will join Relay Therapeutics' board of directors.
Cambridge, Massachusetts-based Kyn Therapeutics, a provider of new immunometabolism therapies for treating cancer, has secured $49 million in Series A funding. The investors were Atlas Venture and OrbiMed.
Instana, a San Mateo, California-based platform that monitors and manages complex big data and microservices, has raised $20 million in Series B funding. Accel led the round with participation from return backer Target Partners.